MARÍA JOSÉ
DEVESA MEDINA
Profesora asociada de Ciencias de la Salud
Hospital Clínico San Carlos de Madrid
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (7)
2020
-
A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus–Advanced Fibrosis
Hepatology, Vol. 72, Núm. 6, pp. 1924-1934
2019
-
HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype
Open Forum Infectious Diseases, Vol. 6, Núm. 5
2017
-
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort
Journal of Viral Hepatitis, Vol. 24, Núm. 4, pp. 304-311
-
Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience
Journal of Viral Hepatitis, Vol. 24, Núm. 6, pp. 464-471
2015
-
Actualización terapéutica en la hepatitis C
Revista Espanola de Quimioterapia, Vol. 28, pp. 48-51
2012
-
Polymorphism of the TLR4 gene reduces the risk of hepatitis C virus-induced hepatocellular carcinoma
Oncology, Vol. 82, Núm. 1, pp. 35-40
2008
-
"12 Weeks' stopping rule" in the treatment of genotype 1 chronic hepatitis C: Two prognostic categories under the same label?
Scandinavian Journal of Gastroenterology, Vol. 43, Núm. 8, pp. 979-983